Welcome to AstraZeneca
As one of the world's leading pharmaceutical companies, our business is focused on turning good ideas into innovative, effective medicines that make a real difference in important areas of healthcare.-
Latest features
-
Latest news collapse
-
16 October 2009
SYMBICORT TURBUHALER Approved for the Treatment of Adult Asthma in Japan
AstraZeneca today announced that Symbicort Turbuhaler (budesonide/formoterol) has been approved by Japan’s Ministry of Health, Labor and Welfare (MHLW) for the maintenance treatment of bronchial asthma in patients aged 16 and over when a combination therapy of an inhaled steroid and a long-acting beta-2 agonist is necessary.
-
16 October 2009
US Food and Drug Administration Approves CRESTOR for Use in Pediatric Patients with Heterozygous Familial Hypercholesterolemia
AstraZeneca today announced the US Food and Drug Administration (FDA) approved CRESTOR (rosuvastatin calcium) for use in children ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol. HeFH, a genetic disease, is characterized by high LDL cholesterol (the “bad” cholesterol) and increased risk of early cardiovascular disease.
-
16 October 2009
SYMBICORT TURBUHALER Approved for the Treatment of Adult Asthma in Japan
